Defining α-synuclein species responsible for Parkinson's disease phenotypes in mice.


Journal

The Journal of biological chemistry
ISSN: 1083-351X
Titre abrégé: J Biol Chem
Pays: United States
ID NLM: 2985121R

Informations de publication

Date de publication:
05 07 2019
Historique:
received: 25 01 2019
revised: 22 05 2019
pubmed: 31 5 2019
medline: 11 3 2020
entrez: 31 5 2019
Statut: ppublish

Résumé

Parkinson's disease (PD) is a neurodegenerative disorder characterized by fibrillar neuronal inclusions composed of aggregated α-synuclein (α-syn). These inclusions are associated with behavioral and pathological PD phenotypes. One strategy for therapeutic interventions is to prevent the formation of these inclusions to halt disease progression. α-Synuclein exists in multiple structural forms, including disordered, nonamyloid oligomers, ordered amyloid oligomers, and fibrils. It is critical to understand which conformers contribute to specific PD phenotypes. Here, we utilized a mouse model to explore the pathological effects of stable β-amyloid-sheet oligomers compared with those of fibrillar α-synuclein. We biophysically characterized these species with transmission EM, atomic-force microscopy, CD spectroscopy, FTIR spectroscopy, analytical ultracentrifugation, and thioflavin T assays. We then injected these different α-synuclein forms into the mouse striatum to determine their ability to induce PD-related phenotypes. We found that β-sheet oligomers produce a small but significant loss of dopamine neurons in the substantia nigra pars compacta (SNc). Injection of small β-sheet fibril fragments, however, produced the most robust phenotypes, including reduction of striatal dopamine terminals, SNc loss of dopamine neurons, and motor-behavior defects. We conclude that although the β-sheet oligomers cause some toxicity, the potent effects of the short fibrillar fragments can be attributed to their ability to recruit monomeric α-synuclein and spread

Identifiants

pubmed: 31142553
pii: S0021-9258(20)31833-0
doi: 10.1074/jbc.RA119.007743
pmc: PMC6615698
doi:

Substances chimiques

Amyloid 0
Protein Aggregates 0
alpha-Synuclein 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

10392-10406

Subventions

Organisme : NINDS NIH HHS
ID : P50 NS108675
Pays : United States

Commentaires et corrections

Type : ErratumIn

Informations de copyright

© 2019 Froula et al.

Références

Biophys J. 2000 Mar;78(3):1606-19
pubmed: 10692345
Neuron. 2000 Jan;25(1):239-52
pubmed: 10707987
Nat Cell Biol. 2002 Feb;4(2):160-4
pubmed: 11813001
Alzheimer Dis Assoc Disord. 2002 Jul-Sep;16(3):191-5
pubmed: 12218651
J Biol Chem. 2003 Apr 25;278(17):15313-8
pubmed: 12586824
Science. 2003 Apr 18;300(5618):486-9
pubmed: 12702875
J Neuropathol Exp Neurol. 2003 Dec;62(12):1241-53
pubmed: 14692700
Anal Biochem. 2008 Feb 15;373(2):330-6
pubmed: 17949677
Curr Protoc Neurosci. 2004 Feb;Chapter 1:Unit 1.2
pubmed: 18428596
Biochem J. 2009 Jul 15;421(3):415-23
pubmed: 19435461
Mol Neurodegener. 2010 Dec 13;5:57
pubmed: 21144050
Front Neuroanat. 2010 Dec 27;4:147
pubmed: 21212837
Proc Natl Acad Sci U S A. 2011 Mar 8;108(10):4194-9
pubmed: 21325059
Neuron. 2011 Oct 6;72(1):57-71
pubmed: 21982369
Biochem J. 2012 May 1;443(3):719-26
pubmed: 22316405
Proc Natl Acad Sci U S A. 2012 Mar 20;109(12):4443-8
pubmed: 22403062
J Exp Med. 2012 May 7;209(5):975-86
pubmed: 22508839
Cell. 2012 May 25;149(5):1048-59
pubmed: 22632969
Science. 2012 Nov 16;338(6109):949-53
pubmed: 23161999
Brain. 2013 Apr;136(Pt 4):1128-38
pubmed: 23466394
Proc Natl Acad Sci U S A. 2013 Aug 13;110(33):E3138-47
pubmed: 23898162
Nat Commun. 2013;4:2575
pubmed: 24108358
Acta Neuropathol Commun. 2014 Aug 06;2:88
pubmed: 25095794
Nat Protoc. 2014 Sep;9(9):2135-46
pubmed: 25122523
Proc Natl Acad Sci U S A. 2014 Oct 7;111(40):E4274-83
pubmed: 25246573
Cell Rep. 2015 Mar 3;10(8):1252-60
pubmed: 25732816
Proc Natl Acad Sci U S A. 2015 Apr 21;112(16):E1994-2003
pubmed: 25855634
Biomolecules. 2015 Apr 23;5(2):617-34
pubmed: 25915624
J Clin Invest. 2015 Jul 1;125(7):2721-35
pubmed: 26075822
Nat Commun. 2015 Jun 16;6:7314
pubmed: 26076669
Neurobiol Dis. 2015 Oct;82:185-199
pubmed: 26093169
Mol Cell. 2015 Sep 3;59(5):781-93
pubmed: 26300264
EMBO J. 2015 Oct 1;34(19):2408-23
pubmed: 26323479
Proc Natl Acad Sci U S A. 2015 Sep 22;112(38):E5308-17
pubmed: 26324905
Antioxid Redox Signal. 2016 Mar 1;24(7):376-91
pubmed: 26564470
J Cell Sci. 2016 May 1;129(9):1792-801
pubmed: 26989132
Sci Transl Med. 2016 Jun 8;8(342):342ra78
pubmed: 27280685
J Biol Chem. 2016 Sep 2;291(36):18675-88
pubmed: 27382062
J Exp Med. 2016 Aug 22;213(9):1759-78
pubmed: 27503075
Acta Neuropathol Commun. 2016 Aug 08;4(1):80
pubmed: 27503460
Cell Rep. 2016 Sep 20;16(12):3373-3387
pubmed: 27653697
Science. 2016 Sep 30;353(6307):
pubmed: 27708076
Cell Rep. 2017 Jan 3;18(1):161-173
pubmed: 28052246
Neurobiol Dis. 2018 Jan;109(Pt B):201-208
pubmed: 28363800
Neurobiol Dis. 2017 Sep;105:84-98
pubmed: 28576704
J Biol Chem. 2017 Aug 11;292(32):13482-13497
pubmed: 28611062
Neurobiol Dis. 2018 Jan;109(Pt B):178-190
pubmed: 28709995
Nat Neurosci. 2017 Nov;20(11):1560-1568
pubmed: 28920936
Science. 2017 Dec 15;358(6369):1440-1443
pubmed: 29242346
J Parkinsons Dis. 2018;8(2):303-322
pubmed: 29400668
Behav Brain Res. 2018 May 2;343:41-49
pubmed: 29407413
Nature. 2018 May;557(7706):558-563
pubmed: 29743672
Handb Clin Neurol. 2018;153:321-335
pubmed: 29887143
Neurobiol Dis. 2019 Apr;124:276-288
pubmed: 30381260
Res Commun Chem Pathol Pharmacol. 1985 Dec;50(3):435-41
pubmed: 3878557
Nature. 1997 Aug 28;388(6645):839-40
pubmed: 9278044
J Comp Neurol. 1997 Nov 17;388(2):211-27
pubmed: 9368838

Auteurs

Jessica M Froula (JM)

From the Department of Neurology, Center for Neurodegeneration and Experimental Therapeutics, University of Alabama at Birmingham, Birmingham, Alabama 35294.

Marta Castellana-Cruz (M)

the Centre for Misfolding Diseases, Department of Chemistry, University of Cambridge, Cambridge CB2 1EW, United Kingdom, and.

Nadia M Anabtawi (NM)

From the Department of Neurology, Center for Neurodegeneration and Experimental Therapeutics, University of Alabama at Birmingham, Birmingham, Alabama 35294.

José D Camino (JD)

the Institute for Biocomputation and Physics of Complex Systems (BIFI)-Joint Unit BIFI-IQFR (CSIC), University of Zaragoza, Zaragoza 50018, Spain.

Serene W Chen (SW)

the Centre for Misfolding Diseases, Department of Chemistry, University of Cambridge, Cambridge CB2 1EW, United Kingdom, and.

Drake R Thrasher (DR)

From the Department of Neurology, Center for Neurodegeneration and Experimental Therapeutics, University of Alabama at Birmingham, Birmingham, Alabama 35294.

Jennifer Freire (J)

From the Department of Neurology, Center for Neurodegeneration and Experimental Therapeutics, University of Alabama at Birmingham, Birmingham, Alabama 35294.

Allen A Yazdi (AA)

From the Department of Neurology, Center for Neurodegeneration and Experimental Therapeutics, University of Alabama at Birmingham, Birmingham, Alabama 35294.

Sheila Fleming (S)

the Department of Pharmaceutical Sciences, Northeast Ohio Medical University, Rootstown, Ohio 44272.

Christopher M Dobson (CM)

the Centre for Misfolding Diseases, Department of Chemistry, University of Cambridge, Cambridge CB2 1EW, United Kingdom, and.

Janet R Kumita (JR)

the Centre for Misfolding Diseases, Department of Chemistry, University of Cambridge, Cambridge CB2 1EW, United Kingdom, and.

Nunilo Cremades (N)

the Institute for Biocomputation and Physics of Complex Systems (BIFI)-Joint Unit BIFI-IQFR (CSIC), University of Zaragoza, Zaragoza 50018, Spain, ncc@unizar.es.

Laura A Volpicelli-Daley (LA)

From the Department of Neurology, Center for Neurodegeneration and Experimental Therapeutics, University of Alabama at Birmingham, Birmingham, Alabama 35294, lvolpicellidaley@uabmc.edu.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH